Poniard Pharmaceuticals, Inc. Overview
Pro stress-test →Poniard Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of cancer therapeutics. Its lead platform product candidate is Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. As of June 2026, the company is trading on OTC Markets at penny-stock levels, indicating significant distress.
Strategic Profile
Pro stress-test →In June 2011, Poniard announced a definitive merger agreement with Allozyne, Inc., a privately held biotechnology company focused on bioconjugated protein therapeutics, which would combine Allozyne's autoimmune disease product pipeline with Poniard's oncology assets. The combined company was expected to focus on advancing Allozyne products and seek a partnership for continued development of picoplatin. The company's current operational status and pipeline progress are unclear based on available public data.
Competitive Landscape
Pro stress-test →In the platinum-based cancer therapy space, Poniard's Picoplatin competed against established chemotherapy agents and next-generation platinum compounds. However, the company's current operational status and pipeline viability are unknown. No active competition profile can be reliably established given the 15-year gap since last documented clinical progress.
Industry Context
Poniard Pharmaceuticals, Inc. operates in Biopharmaceuticals / Oncology.
Key facts
Founded: 2006 (as Poniard; formerly NeoRx Corporation) · Headquarters: San Leandro, US · Employees: Not available · Revenue: Not available · Market cap: $0.00015B (OTC penny stock)